Editorial
Have the roles of two functional polymorphisms in breast cancer, R72P in P53 and MDM2-309 in MDM2, become clearer?
-
Correspondence: Rodney J Scott rodney.scott@newcastle.edu.au
Discipline of Medical Genetics, Faculty of Health, University of Newcastle, Newcastle, NSW 2308, Australia; Centre for Information Based Medicine, Hunter Medical Research Institute, John Hunter Hospital, Newcastle, NSW 2305, Australia; and Division of Genetics, Hunter Area Pathology Service, John Hunter Hospital, Newcastle, NSW 2305, Australia
Breast Cancer Research 2010, 12:102 doi:10.1186/bcr2474
See related research article by Schmidt et al., http://breast-cancer-research.com/content/11/6/R89
Published: 3 February 2010Abstract
Genetic differences between individuals have been predicted to account for disparate outcomes in patients diagnosed with cancer. The search for genetic determinants has been ongoing for a considerable amount of time and it is only now that insights have been gained into which polymorphisms are most likely to be important in determining not only disease likelihood but also outcome. The quest to be able to accurately predict patient outcomes in breast cancer may now be a step closer as increased sample size is leading to more robust statistical analysis and a better understanding of molecular mechanisms of disease are forthcoming.